Crescent Biopharma Inc. (CBIO)
NASDAQ: CBIO
· Real-Time Price · USD
13.80
0.20 (1.47%)
At close: Aug 20, 2025, 3:59 PM
13.80
0.00%
After-hours: Aug 20, 2025, 04:10 PM EDT
Company Description
Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients.
Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors.
The company is headquartered in Waltham, Massachusetts.
Crescent Biopharma Inc.
| Country | United States |
| IPO Date | Jan 10, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Joshua T. Brumm |
Contact Details
Address: 300 5th Avenue Waltham, Massachusetts United States | |
| Website | https://crescentbiopharma.com |
Stock Details
| Ticker Symbol | CBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001124105 |
| CUSIP Number | 14888D208 |
| ISIN Number | US4037831033 |
| Employer ID | 56-2020050 |
| SIC Code | 2834 |
Key Executives
No executives data available.Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 11, 2025 | 10-Q | Quarterly Report |
| Aug 11, 2025 | 8-K | Current Report |
| Aug 07, 2025 | 4 | Filing |
| Jun 06, 2025 | 4 | Filing |
| Jun 06, 2025 | 4 | Filing |
| Jun 06, 2025 | 4 | Filing |
| Jun 06, 2025 | 4 | Filing |
| Jun 06, 2025 | 4 | Filing |
| Jun 06, 2025 | 8-K | Current Report |
| May 29, 2025 | 4 | Filing |